Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 62

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 62
---
 valuesfor awardsgrantedin prioryears thatfailed tomeetvestingconditions($) |          |   |     | TotalAdjustmentsfor EquityAwards($) |            |   |     | CompensationActually 
 Paid($)              |           |   |
| 2024 |     |                                                         | 1,192,879 |     |                                                                  | (559,772   | ) |     |                                                                |    46,357 |     |                                                                                         | (165,517 | ) |     |                                                                    |       — |     |                                                                                                                    | (371,986 | ) |     |                                                                                              | (143,693 | ) |     |                                     | (1,194,611 | ) |     |                      |    (1,732 | ) |
| 2023 |     |                                                         | 2,329,573 |     |                                                                  | (1,708,194 | ) |     |                                                                | 1,047,596 |     |                                                                                         |  437,433 |   |     |                                                                    | 299,750 |     |                                                                                                                    |  400,251 |   |     |                                                                                              | —        |   |     |                                     |    476,836 |   |     |                      | 2,806,409 |   |
| 2022 |     |                                                         |   987,849 |     |                                                                  | (436,149   | ) |     |                                                                |    51,669 |     |                                                                                         | (680,104 | ) |     |                                                                    |       — |     |                                                                                                                    |  (76,756 | ) |     |                                                                                              | —        |   |     |                                     | (1,141,340 | ) |     |                      |  (153,491 | ) |

| (7) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our stock price at the end and the beginning of the measurement period by our stock price at the beginning of the measurement period. |

| (8) | The dollar amounts reported represent the amount of net loss reflected in our audited financial statements for the applicable year. |

Analysis of the Information Presented in the Pay Versus Performance Table As described in more detail above in “Executive Compensation” our executive compensation program reflects a performance-driven compensation philosophy. While we utilize several performance measures to align executive compensation with company performance, those company performance measures are not